Načítá se...
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium–glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering age...
Uloženo v:
| Vydáno v: | Int J Mol Sci |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5454992/ https://ncbi.nlm.nih.gov/pubmed/28524098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18051083 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|